!!News!! - 500 Beiträge pro Seite

[sharpy]

...und noch nicht bei finance.yahoo.com erschienen!

13 Januar 2005 12:00 PM Zeitzone Berlin

Illumina Launches DASL Assay and Cancer Panel for Gene Expression Profiling of Paraffin-Embedded Samples

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--Jan. 13, 2005--
Assay Enables Reproducible, High-Multiplex Analysis of Degraded RNAs and Development of Molecular Profiles Associated with Clinical Outcomes





Illumina, Inc. (NASDAQ:ILMN) announced today the commercial availability of its new DASL(TM) assay for generating reproducible gene expression profiles from formalin-fixed, paraffin-embedded (FFPE) samples and other samples containing partially degraded RNAs. The DASL assay enables researchers to measure RNA abundance of over 500 genes in parallel per sample. The assay probes three unique sequences per target gene and PCR amplification is limited to genes of interest, resulting in high specificity and sensitivity when hybridized and detected on Illumina`s Sentrix(R) Arrays. Illumina also released a standard DASL cancer panel. The two new offerings are part of a growing portfolio of gene expression products from Illumina.

It has been estimated that there are over 400 million FFPE tissue samples archived in North America for cancer alone. Many of these samples represent known clinical outcomes -- a potential gold mine of information when linked with underlying gene expression profiles, and an exciting prospect for the validation and testing of biomarkers associated with cancer or with other complex diseases. To date, degraded RNA samples have been reliably assayed only with expensive, low-multiplex qPCR approaches. Illumina`s DASL assay opens up a new avenue for reproducible RNA profiling at high multiplex and at low cost per sample.

The DASL (cDNA-mediated Annealing, Selection, extension and Ligation) assay has been tested extensively with nine different institutions over a two-year period. The tests have processed over one thousand unique samples representing a range of biology and disease. Results from two of the studies (with Veridex, LLC, a Johnson & Johnson Company, and with the Veterans Administration Medical Center, San Diego) have been documented in recent scientific publications (See Editors` Note).

"By focusing exclusively on target sites, the DASL assay provides precise measurements of the parts of the genome that are relevant to the problem at hand. We typically find nearly all of the genes queried by the cancer panel, including the low expressers," stated Richard B. Everson, M.D., M.P.H., principal investigator of a beta-site study. Everson is also a professor of medicine at Wayne State University and professor of oncology at the Barbara Ann Karmanos Cancer Institute. "We have profiled a significant number of FFPE cancer samples with the DASL assay," Everson continued, "and we`ve observed high sample-to-sample reproducibility. We`re looking forward to developing molecular profiles that will help characterize the progression of prostate and other cancers and provide meaningful value to clinical management."

"Illumina`s DASL assay gives the research community an important tool for tapping into the vast repositories of paraffin-embedded tissue samples, extracting meaningful genome-wide expression data and advancing our understanding of disease," remarked Jay Flatley, Illumina President and CEO. "By delivering reproducible performance, high throughput and low per-sample costs, we believe that our DASL assay can truly streamline discovery processes. Illumina`s assay development skills are proving to be a powerful complement to our BeadArray technology and a further enabler of large-scale, biological experimentation."

Illumina BeadStation or BeadLab customers can utilize their existing systems to run the DASL assay with the addition of an accessory kit. The DASL assay is supported by two different BeadArray formats -- the 96-sample Sentrix Universal Array Matrix and the 16-sample Sentrix Universal BeadChip. Depending on study size, running costs per sample (array and reagents) can be less than $100. More information about the DASL assay can be found at: http://www.illumina.com/products/geneexpression/dasl_assay.i… .

Illumina`s gene expression portfolio includes multi-sample standard and custom arrays that use direct hybridization approaches for validation and RNA profiling. In addition, the Company will soon make broadly available two microarrays for genome-wide analysis: the Human-6 BeadChip and the HumanRef-8 BeadChip.

Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company`s proprietary BeadArray(TM) technology -- now used in leading genome centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina`s litigation with Affymetrix, market acceptance of Illumina`s BeadArray-based products, Illumina`s ability to fully develop and commercialize its BeadArray technologies, the Company`s ability to successfully commercialize its integrated BeadLab and BeadStation systems for high-throughput genetic analysis, to continue to attract and retain customers in its services and oligonucleotide synthesis operations, to fully develop its BeadArray technologies, to develop and deploy new gene expression profiling and proteomics applications for its platform technology, to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, and other factors detailed in the Company`s filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Editors` Note

The DASL assay was the subject of three scientific papers published in 2004. According to the American Journal of Pathology, a leading journal in the pathology field, the November DASL paper is ranked third among the top 50 most frequently read articles in the journal. The three references are cited below.

Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded Tissues Obtained with a Novel Assay for Microarray Analysis, Bibikova M, Yeakley JM, Chudin E, Chen J, Wickham E, Wang-Rodriguez J, Fan JB, Clinical Chemistry, Volume 50, No.12, 2384-2386, December 2004.

Quantitative Gene Expression Profiling in Formalin-Fixed, Paraffin-Embedded Tissues Using Universal Bead Arrays, Marina Bibikova, Dimitri Talantov, Eugene Chudin, Joanne M. Yeakley, Jing Chen, Dennis Doucet, Eliza Wickham, David Atkins, David Barker, Mark Chee, Yixin Wang and Jian-Bing Fan, American Journal of Pathology, Vol. 165, No.5, 1799-1807, November 2004.

A Versatile Assay for High-Throughput Gene Expression Profiling on Universal Array Matrices, Jian-Bing Fan, Joanne M. Yeakley, Marina Bibikova, Eugene Chudin, Eliza Wickham, Jing Chen, Dennis Doucet, Philippe Rigault, Baohong Zhang, Richard Shen, Celeste McBride, Hai-Ri Li, Xiang-Dong Fu, Arnold Oliphant, David L. Barker, and Mark S. Chee, Genome Research, 14 , 878-885, 2004.

To access a list of additional Illumina publications, visit www.illumina.com/technology/publications/tech_pub_sciencepub.ilmn

[Schacke]

scheint keinen zu interessieren oder ?

[scrabbler]

Nachricht wurde erst eben auf finance.yahoo.com veröffentlicht, mal sehen
eigentlich sind die News ganz gut

[cnsky]

hi leute
was denkt ihr wie die zahlen am 21.02.05 ausfallen werden?
ich denke wir werden viel spass mit illumina haben !!
echt guter chart,vieleicht sehen wir ja dieses jahr april/mai noch die 12€ ?!


gruss
cnsky

[cnsky]

sehr schöner chart bei illumina und
so wie das volumen gestiegen ist 1.1 mio. werden die zahlen wohl der hammer werden.
ich freue mich drauf auf den 21.2.05.
gruss cnsky

[Realtimelooser]

was ich nicht verstehe, wieso in Deutschland so gut wie kein Handel ist. München 100 Stücke.

[cnsky]

ich verstehe das auch nicht,kann mir nur denken das die meisten auf dieses papier noch nicht aufmerksam geworden sind.
aber die können ja dann bei 10-12€ noch einsteigen,ist ja auch noch nicht zu spät bei dem potenzial was illumina hat.

gruss cnsky

[Realtimelooser]

Hi cnsky, habe die Teile seit 3 Jahren im Depot und bisher nicht so viel Freude. Bin leider auch nicht mehr so auf dem laufenden, was das pontenzial anbelangt. Kannst Du mal durchgeben wie es so um ILMN bestellt ist und wohin die Reise gehen könnte? Wäre nett,

Gruß RTL

[cnsky]

sorry rtl,
kann dir nur auf die schnelle nur das yahoo-board empfehlen,
da ich gleich in den ski-urlaub fahre und da lasse ich es mir gut gehen.

gruss cnsky

[Realtimelooser]

Na dann wünsch ich Dir viel Spaß und meide die Lawinen...